IP Library Granted Patent US 9,012,457
Granted Patent B2
US 9,012,457 · App. 13/994,998 · Granted Apr 21, 2015

2-carboxamide-4-piperazinyl-benzofuran derivative

Inventors: Helena Gybäck (Macclesfield, GB); Jonas Malmström (Macclesfield, GB); Elgaard Gitte Terp (Macclesfield, GB)
Assignee: AstraZeneca AB
C07D405/12C07D215/227C07D307/85
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,012,457
App. No.
13/994,998
Granted
Apr 21, 2015
Kind
B2
Abstract

The present invention relates to a compound of formula (I), and to pharmaceutical compositions containing said compound and to the use of said compound in therapy, for instance in treating cognitive disorders, as well as to intermediates useful in the preparation thereof.

Claims (11)

1. A compound of formula (I), N-Methyl-4-[4-[2-(1-methyl-2-oxo-3,4-dihydroquinolin-5-yl)ethyl]piperazin-1-yl]benzofuran-2-carboxamide,

or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising as active ingredient a therapeutically effective amount of a compound according to claim 1 in association with a pharmaceutically acceptable excipient, carrier or diluent.

3. A method of treating Alzheimer's Disease in a patient in need of such treatment, comprising administering to the patient a therapeutically effective amount of a compound according to claim 1 .

4. A method of treating a mood disorder in a patient in need of such treatment, comprising administering to the a therapeutically effective amount of a compound according to claim 1 .

5. A compound according to formula (II)

wherein R1 is C 1-4 alkyl.

6. A compound according to claim 5 , which is N-Methyl-4-piperazin-1-yl-benzofuran-2-carboxamide.

7. A compound according to formula (III)

wherein R2 is C 1-4 alkyl.

8. A compound according to claim 7 , which is 2-(1-Methyl-2-oxo-3,4-dihydroquinolin-5-yl)acetaldehyde.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 5, 2019
From: ASTRAZENECA AB
To: ACTURUM LIFE SCIENCE AB
Reel/Frame 049674/0593 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 5, 2019
From: ACTURUM LIFE SCIENCE AB
To: ACTURUM REAL ESTATE AB
Reel/Frame 049674/0873 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 5, 2019
From: ACTURUM REAL ESTATE AB
To: ACTURUM LIFE AB
Reel/Frame 049675/0145 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 30, 2013
From: GYBACK, HELENA; MALMSTROM, JONAS; TERP, ELGAARD GITTE
To: ASTRAZENECA AB
Reel/Frame 031118/0421 →
Continuity (2)
Provisional Application 61424944 · Dec 20, 2010
Related Publication 20140329830A1 · Nov 6, 2014